Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.

Éveline Boucher(Boston Scientific (United States)), Yves Deugnier(Inserm), Annick Ruffault(Hôpital Pontchaillou), Christian Jacquelinet(Université Paris-Sud), Patrice André, Bruno Turlin(Inserm), Pierre Brissot(Inserm), Romain Moirand(Inserm), Dominique Guyader(Inserm), Hervé Jouanolle(Inserm)

PubMed

February 1, 1995

Cited by 66

Related Papers

A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload

|Journal of Biological Chemistry|2001|1.7k

Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis

|Nature Genetics|2003|976

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

|Journal of Clinical Oncology|2013|775

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

|Journal of Clinical Oncology|2013|596

Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.

|Molecular Pharmacology|1993|536